Duane Banet, MD
Dermatology · New Albany, INNPI 1245211937
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,288 of the $1,557 with a category attached, or 82.7%. 13 manufacturers reported payments, led by Johnson & Johnson at 43.8% of the total. Reporting peaked in 2023 at $388 and has fallen 87.8% since, to $47 in 2025. That places this record below the midpoint for dermatology clinicians in IN, where the typical reported total is $3,818.
Across 88 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$681
- AbbVie$583
- Novartis$117
- LEO Pharma Inc.$32
- Biofrontera Inc.$21
- E.r. Squibb & Sons, L.L.C.$20
- plus $103 from 7 others
Across 39 payments — averaging $2047.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$66K
- Janssen Research & Development, LLC$7K
- Dr.reddy's Laboratories,inc.$6K
What the payments were for
- Food & beverage$1,28883%
- Education$26917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $681 |
| AbbVie(2 entities) | 38 | $583 |
| Novartis | 6 | $117 |
| LEO Pharma Inc. | 2 | $32 |
| Biofrontera Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Sanofi | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Prugen, Inc. Pharmaceuticals | 1 | $12 |
How this compares
$1,557 in reported general payments places this provider in the 35th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imiquimod | 134 | $2,076 |
| Doxepin Hcl | 37 | $1,083 |
| Clindamycin Phosphate | 30 | $973 |
| Triamcinolone Acetonide | 96 | $730 |
| Cephalexin | 91 | $577 |
| Mupirocin | 78 | $491 |
| Clobetasol Propionate | 22 | $481 |
| Hydrocortisone | 101 | $471 |
| Doxycycline Hyclate | 30 | $466 |
| Hydroxyzine Hcl | 16 | $455 |
| Mometasone Furoate | 11 | $149 |
| MethotrexateMethotrexate Sodium | 13 | $104 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Albany
- Alfred KnableNew Albany$203K
- Ashley ReaderNew Albany$15K
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
- Jeffrey SassmannshausenFort Wayne$489K
- Nikolajs PerdueIndianapolis$302K
- Michael SheehanColumbus$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.